D-[Ala1]-peptide T-amide is transported from blood to brain by a saturable system. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


D-[Ala1]-peptide T-amide is transported from blood to brain by a saturable system.

Brain Res Bull. 1987 Dec;19(6):629-33. Unique Identifier : AIDSLINE MED/88150571
Barrera CM; Kastin AJ; Banks WA; Veterans Administration Medical Center, New Orleans, LA 70146.

Abstract: It is becoming increasingly evident that peptides can cross the blood-brain barrier. The entry into the central nervous system of a commercially available analog of Peptide T, an octapeptide derived from the human immunodeficiency virus envelope glycoprotein 120, was studied in several experiments. It was found that 125I-Peptide T analog given intravenously in the periphery entered the brain in an intact form, as confirmed by HPLC, to a greater extent than did the labeled albumin control. This entry occurred despite the very low lipid solubility, measured by the octanol/buffer partition coefficient, for the iodinated analog. The rate of entry was decreased by unlabeled Peptide T analog, but not by iodo-tyrosine. Saturable transport out of the brain was not observed after intraventricular administration. Thus, results with 125I-Peptide T analog indicate that saturable systems can transport peptides from the blood into the central nervous system.
Keywords: Animal *Blood-Brain Barrier Chromatography, High Pressure Liquid Iodine Radioisotopes/DIAGNOSTIC USE Kinetics Male Mice Mice, Inbred ICR Oligopeptides/BLOOD/*METABOLISM Support, U.S. Gov't, Non-P.H.S. Technetium Tc 99m Aggregated Albumin/DIAGNOSTIC USE JOURNAL ARTICLE

KWDanimalKWDblood-brainbarrierchromatography,highpressureliquidiodineradioisotopes/diagnosticusekineticsmalemicemice,inbredicroligopeptides/blood/KWDmetabolismsupport,uKWDsKWDgov't,non-pKWDhKWDsKWDtechnetiumtc99maggregatedalbumin/diagnosticusejournalarticle
880630
M8860454

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .